Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Bullfrog AI Holdings, Inc. Warrants (BFRGW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: BFRGW (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 61.76% | Avg. Invested days 72 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.14 - 1.37 | Updated Date 02/26/2025 |
52 Weeks Range 0.14 - 1.37 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Bullfrog AI Holdings, Inc. Warrants
Company Overview
History and Background
Bullfrog AI Holdings, Inc. Warrants are derivative securities related to the underlying Bullfrog AI Holdings, Inc. stock (BFRG). They grant the holder the right to purchase shares of BFRG at a specified price before a certain date. Bullfrog AI Holdings, Inc., was founded to revolutionize drug development through its proprietary bfLEAPu2122 analytics platform. Its mission is to significantly reduce the time and cost associated with bringing life-saving treatments to market.
Core Business Areas
- AI-Powered Drug Development: Bullfrog AI focuses on leveraging its bfLEAPu2122 platform to accelerate drug discovery and development by analyzing complex datasets to identify patterns and predict clinical outcomes.
Leadership and Structure
Details about the warrants' issuer and the overall leadership of Bullfrog AI Holdings, Inc. are relevant. The leadership typically consists of a CEO, CFO, and a board of directors overseeing the company's strategic direction. The structure involves departments dedicated to research and development, sales, and operations, among others.
Top Products and Market Share
Key Offerings
- bfLEAPu2122 Analytics Platform: bfLEAPu2122 is Bullfrog AI's core product, a platform designed to analyze complex biological data to accelerate drug development. It aims to improve clinical trial success rates and reduce the time to market for new therapies. Competitors include companies offering similar AI-driven drug discovery platforms such as Schrodinger (SDGR), Recursion Pharmaceuticals (RXRX), and Exscientia (EXAI).
Market Dynamics
Industry Overview
The pharmaceutical and biotechnology industry is undergoing a digital transformation with increased adoption of AI and machine learning to improve drug discovery, clinical trial design, and patient outcomes. The market is highly competitive, with numerous companies developing AI-based solutions.
Positioning
Bullfrog AI is positioned as a provider of advanced AI analytics for drug development, focusing on its ability to handle complex multi-omics data. Its competitive advantage lies in its proprietary bfLEAPu2122 platform and its potential to significantly improve the efficiency of drug development.
Total Addressable Market (TAM)
The total addressable market for AI in drug discovery is estimated to reach billions of dollars in the coming years. Bullfrog AI aims to capture a significant share of this market by offering a comprehensive analytics platform that addresses the challenges of complex data analysis in drug development.
Upturn SWOT Analysis
Strengths
- Proprietary bfLEAPu2122 platform
- Expertise in multi-omics data analysis
- Potential to accelerate drug development
- Focus on improving clinical trial success rates
Weaknesses
- Dependence on successful commercialization of bfLEAPu2122
- Limited track record compared to established competitors
- Potential challenges in scaling operations
- Reliance on securing funding for ongoing research and development
Opportunities
- Growing demand for AI-powered drug discovery solutions
- Potential partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
- Increasing adoption of multi-omics data analysis
Threats
- Intense competition from established AI and pharmaceutical companies
- Regulatory hurdles in drug development
- Technological advancements by competitors
- Economic downturn affecting funding for biotech research
Competitors and Market Share
Key Competitors
- SDGR
- RXRX
- EXAI
- CRSP
Competitive Landscape
Evaluate Bullfrog AI Holdings, Inc.u2019s advantages and disadvantages compared to its competitors. BFRG's warrants (BFRGW) value is tied to BFRG stock.
Growth Trajectory and Initiatives
Historical Growth: Discuss Bullfrog AI Holdings, Inc.'s growth trends over the past years (BFRG)
Future Projections: Provide projections for Bullfrog AI Holdings, Inc.'s future growth based on analyst estimates (BFRG)
Recent Initiatives: Highlight recent strategic initiatives undertaken by Bullfrog AI Holdings, Inc. (BFRG)
Summary
Bullfrog AI is a relatively new player in the AI-driven drug discovery space, offering a promising platform with the potential to accelerate drug development. Its success hinges on the commercialization and adoption of its bfLEAPu2122 platform. Investors should be mindful of the competitive landscape and the inherent risks associated with early-stage biotechnology companies. The warrants are a derivative financial product and their value is directly linked to the performance of the underlying stock of BFRG. Investors must assess if BFRG can bring the innovative solution to the market to increase value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. The data presented is based on publicly available information and may not be entirely accurate. Investment decisions should be made based on your own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bullfrog AI Holdings, Inc. Warrants
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-02-14 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 2 | Website |
Full time employees 2 | Website | ||
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.